Mounjaro Usage Doubles in June Sales Surge by 18 in India

Eli Lilly’s blockbuster drug Mounjaro (tirzepatide) has witnessed a remarkable surge in usage and sales in India, with June 2025 figures showing a twofold increase in volume to 87,968 units, compared to 42,281 units in May. The sales value rose by 18.2%, reaching ₹50 crore, up from ₹42.28 crore in the previous month.

The growth, tracked by PharmaRack, is attributed to faster onboarding of new patients and strong adherence among existing users. The 2.5 mg vial sales doubled from 19,346 to 39,042 units, reflecting new patient onboarding, while the 5 mg vial sales increased from 23,935 to 48,944 units, indicating adherence to prescribed dosage escalation.

Mounjaro is a once-weekly injectable targeting type 2 diabetes and chronic weight management in adults with a BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities. It activates both GIP and GLP-1 hormone receptors, setting it apart from earlier therapies.

Since its launch in March 2025, Mounjaro has shown consistent growth in India’s ₹628 crore anti-obesity market, where it now holds 8% market share. However, semaglutide (Rybelsus and Wegovy) remains the leader with 66% market dominance.

As semaglutide’s patent expiration in January 2026 approaches, Indian pharma giants like Zydus, Dr. Reddy's, and Cipla are gearing up to introduce generic versions, potentially reshaping the market. Globally, the anti-obesity market is projected to hit $130 billion by 2030, with India emerging as a critical growth hub.